Suspended

The CONQUEST-Study. Evaluation of Clinical Endpoints for Treatment-induced Changes in GERD-related Symptoms

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Pantoprazole

Drug
Who is being recruted

Non-Erosive Reflux Disease+4

+ Deglutition Disorders

+ Digestive System Diseases

Over 18 Years
+11 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 4
Interventional
Study Start: March 2007
See protocol details

Summary

Principal SponsorTakeda
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: March 1, 2007

Actual date on which the first participant was enrolled.

The aim of the study is to compare two different endpoint measures: heartburn as assessed by the physicians versus gastroesophageal reflux disease (GERD)-related symptoms as assessed by the patient using the ReQuest™ questionnaire. The assessment is made in GERD-patients treated with a daily dose of 40 mg oral pantoprazole over an 8-week period.

Official TitleThe CONQUEST-Study. Evaluation of Clinical Endpoints for Treatment-induced Changes in GERD-related Symptoms
NCT00449813
Principal SponsorTakeda
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

40 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Non-Erosive Reflux DiseaseDeglutition DisordersDigestive System DiseasesEsophageal DiseasesGastroesophageal RefluxGastrointestinal DiseasesEsophageal Motility Disorders

Criteria

4 inclusion criteria required to participate
Written informed consent
Outpatients of at least 18 years of age
History of GERD-related symptoms of at least 6 months prior to baseline visit
Endoscopically-confirmed GERD or non-erosive GERD
7 exclusion criteria prevent from participating
Zollinger-Ellison syndrome or other gastric hypersecretory condition
Acute peptic ulcer and/or ulcer complications
Pyloric stenosis
Severe or unstable cardiovascular, pulmonary, and/or endocrine disease
Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Active Comparator
40 mg Pantoprazole

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 15 locations

Suspended

Altana Pharma/Nycomed

BT Oss, NetherlandsOpen Altana Pharma/Nycomed in Google Maps
Suspended

Altana Pharma/Nycomed

Den Helder, Netherlands
Suspended

Altana Pharma/Nycomed

EH Geldrop, Netherlands
Suspended

Altana Pharma/Nycomed

Basel, Switzerland
Suspended15 Study Centers